Ivermectin & Glioblastoma
Last updated: February 2026
Ivermectin, an FDA-approved antiparasitic drug, shows promising anticancer effects against glioblastoma multiforme (GBM) in preclinical studies. Research demonstrates multiple mechanisms including Akt/mTOR pathway inhibition, mitochondrial dysfunction induction, and anti-angiogenic activity โ all targeting the most aggressive primary brain cancer with a median survival of just 12-15 months.
๐ฌ Key Findings
Multiple preclinical studies have investigated ivermectin's effects on glioblastoma cells. The following are the major findings from peer-reviewed research:
- Growth inhibition: Ivermectin inhibits proliferation of human glioblastoma U87 and T98G cell lines in a dose-dependent manner [1] [2]
- Apoptosis induction: Triggers caspase-dependent programmed cell death, with upregulation of p53 and Bax and downregulation of Bcl-2 [2]
- Anti-angiogenic activity: Inhibits capillary network formation and endothelial cell proliferation, cutting off tumor blood supply [1]
- Autophagy induction: Promotes autophagy-mediated cell death through AKT/mTOR pathway suppression [3]
- In vivo efficacy: Significantly suppresses tumor growth in two independent glioblastoma xenograft mouse models [1]
- Cell cycle arrest: Blocks cells in G0/G1 phase by downregulating CDK2, CDK4, CDK6, cyclin D1, and cyclin E [2]
- Glycolysis inhibition: Accelerates autophagic cell death by blocking GLUT4-mediated JAK/STAT signaling [5]
- Intranasal delivery: Nanoencapsulated ivermectin delivered intranasally shows targeted glioblastoma suppression in preclinical models [7]
โ๏ธ Mechanisms of Action
Research has identified several molecular pathways through which ivermectin exerts anti-tumor effects in glioblastoma cells:
1. Akt/mTOR Pathway Suppression
Ivermectin suppresses phosphorylation of Akt, mTOR, and ribosomal S6 in glioblastoma cells. The Akt/mTOR pathway is a central regulator of cell survival, growth, and proliferation โ its inhibition leads to reduced tumor cell viability and increased autophagy [1] [3].
2. Mitochondrial Dysfunction & Oxidative Stress
Ivermectin decreases mitochondrial respiration, membrane potential, and ATP levels while increasing mitochondrial superoxide production. This creates lethal oxidative stress in tumor cells. The effects are reversed in mitochondria-deficient cells or with antioxidant treatment, confirming the mitochondrial mechanism [1].
3. Autophagy-Mediated Cell Death
By blocking the AKT/mTOR signaling axis, ivermectin triggers autophagy โ a cellular self-digestion process. In glioma cells, this autophagy is cytotoxic rather than protective, leading to autophagic cell death [3].
4. PAK1 Inhibition
P21-activated kinase 1 (PAK1) is an oncogenic kinase involved in proliferation, metastasis, and angiogenesis. Ivermectin inhibits PAK1, disrupting downstream signaling cascades that promote tumor growth. This mechanism has been demonstrated across multiple cancer types [4].
5. Glycolysis Blockade (JAK/STAT)
Ivermectin blocks GLUT4-mediated glucose uptake and inhibits the JAK/STAT signaling pathway, starving glioma cells of their glycolytic fuel and accelerating autophagic death [5].
6. Anti-Angiogenesis
GBM is one of the most vascularized brain tumors. Ivermectin inhibits capillary network formation and suppresses proliferation and survival of human brain microvascular endothelial cells (HBMECs), targeting the tumor's blood supply [1].
๐ Research Timeline
Mitochondrial dysfunction and anti-angiogenesis in GBM
Liu et al. demonstrated that ivermectin inhibits glioblastoma growth in vitro and in two xenograft mouse models by inducing mitochondrial dysfunction, oxidative stress, and suppressing the Akt/mTOR pathway. Also showed anti-angiogenic effects on brain endothelial cells.
Liu Y, et al. Biochem Biophys Res Commun. 2016;480(3):415โ421. PMID: 27771251
Cell cycle arrest and apoptosis in glioma
Song et al. showed ivermectin induces dose-dependent growth inhibition, G0/G1 cell cycle arrest (via CDK2/4/6 downregulation), and caspase-dependent apoptosis in glioma cells both in vitro and in vivo.
Song D, et al. J Cell Biochem. 2019;120(1):622โ633. PMID: 30596403
Autophagy via AKT/mTOR in glioma
Ivermectin was shown to induce autophagy-mediated cell death in glioma cells through inhibition of the AKT/mTOR signaling pathway, paralleling PAK1/Akt/mTOR axis disruption seen in breast cancer.
Liu J, et al. Biosci Rep. 2019;39(12):BSR20192489. PMC6900471
Broad anticancer review including GBM
Comprehensive review of ivermectin's anticancer properties across tumor types. Confirmed dose-dependent inhibition in U87 and T98G GBM cells and caspase-dependent apoptosis. Highlighted multiple mechanisms including PAK1 inhibition, WNT-TCF pathway modulation, and mitochondrial respiration disruption.
Tang M, et al. Pharmacol Res. 2021;163:105207. PMC7505114
Glycolysis inhibition via GLUT4/JAK/STAT
Feng et al. discovered that ivermectin accelerates autophagic glioma cell death by inhibiting glycolysis through blocking GLUT4-mediated JAK/STAT signaling pathway activation, revealing a metabolic vulnerability.
Feng M, et al. Environ Toxicol. 2022;37(4):754โ765. DOI: 10.1002/tox.23440
Comprehensive review: ivermectin as glioma therapeutic strategy
Hu et al. published a comprehensive review consolidating all known anti-glioma mechanisms of ivermectin, including selective targeting of tumor-specific proteins, programmed cell death induction, and modulation of tumor-related signaling pathways.
Hu X, et al. J Neurosci Res. 2024;102(1):e25254. PMID: 37814994
Ivermectin + ATRA repurposing for GBM
Preprint study combining ivermectin with all-trans retinoic acid (ATRA) showed promising results against glioblastoma multiforme, providing evidence for drug combination approaches.
medRxiv preprint. 2024. DOI: 10.1101/2024.08.26.24312575
Intranasal nanoparticle delivery for brain targeting
First study exploring direct ivermectin delivery to the brain. Nanoencapsulated ivermectin administered intranasally showed targeted glioblastoma suppression, addressing the blood-brain barrier challenge.
Published 2025. PMID: 40497800
Review: Repurposing ivermectin for GBM
Latest review article consolidating the case for ivermectin repurposing in glioblastoma, addressing critical issues around bioavailability, dosing, and translational challenges.
Med Chem Res. 2025. DOI: 10.1007/s00044-025-03435-z
๐ Dosing Context
| Context | Dose | Notes |
|---|---|---|
| FDA-approved antiparasitic | 0.15โ0.2 mg/kg (single dose) | Standard human dose for parasitic infections |
| In vitro GBM studies | 5โ40 ฮผM | Concentration range showing anti-tumor effects in cell culture |
| In vivo mouse xenografts | 10โ40 mg/kg | Doses used in mouse tumor models (not directly translatable to humans) |
| Off-label cancer protocols (anecdotal) | 0.5โ2 mg/kg | Reported in alternative medicine contexts; no clinical trial data for GBM |
Blood-brain barrier challenge: A major limitation is whether oral ivermectin achieves therapeutic concentrations in brain tissue. Ivermectin is a substrate of P-glycoprotein efflux pumps at the BBB, which may limit brain penetration. The 2025 intranasal nanoparticle study [7] represents an attempt to address this challenge.
Mouse-to-human dose scaling: Doses effective in mouse xenograft models (10โ40 mg/kg) cannot be directly translated to human doses. Allometric scaling and species-specific pharmacokinetics must be considered. The effective in vitro concentrations (5โ40 ฮผM) may be difficult to achieve with standard oral dosing.
โ ๏ธ Limitations & Important Context
- No clinical trials for GBM: As of early 2026, there are no published results from controlled clinical trials testing ivermectin specifically in glioblastoma patients.
- Preclinical only: All anti-GBM evidence comes from cell culture (in vitro) and animal models (in vivo). Many drugs that work in these settings fail in human trials.
- Not FDA-approved for cancer: Ivermectin is approved only for parasitic infections and rosacea. Any use for cancer is entirely off-label and experimental.
- Blood-brain barrier: Achieving therapeutic concentrations in brain tissue with oral dosing remains unproven. The BBB significantly limits drug delivery to brain tumors.
- Dose concerns: The doses showing anti-tumor effects in animal models are substantially higher than standard antiparasitic doses. Safety at these levels in humans for sustained periods is not established.
- No head-to-head comparisons: No studies have compared ivermectin to standard GBM treatments (temozolomide + radiation) in clinical settings.
- Publication bias: Negative results are less likely to be published, potentially overstating the evidence base.
- Combination data is early: While the ivermectin + ATRA preprint is promising, it has not been peer-reviewed and no TMZ synergy data exists in clinical settings.
Standard of care for GBM: The current standard treatment for glioblastoma is maximal surgical resection followed by radiation with concurrent and adjuvant temozolomide (the Stupp protocol). Median survival is approximately 14โ17 months. Patients should not delay or replace proven treatments with experimental approaches.
๐ References
- Liu Y, Fang S, Sun Q, Liu B. Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress. Biochem Biophys Res Commun. 2016;480(3):415โ421. PMID: 27771251
- Song D, Liang H, Qu B, et al. Ivermectin inhibits the growth of glioma cells by inducing cell cycle arrest and apoptosis in vitro and in vivo. J Cell Biochem. 2019;120(1):622โ633. PMID: 30596403
- Liu J, Liang H, Chen C, et al. Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells. Biosci Rep. 2019;39(12):BSR20192489. PMC6900471
- Tang M, Hu X, Wang Y, et al. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res. 2021;163:105207. PMC7505114
- Feng M, Xu L, He Y, et al. Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation. Environ Toxicol. 2022;37(4):754โ765. DOI: 10.1002/tox.23440
- Hu X, et al. Ivermectin as a potential therapeutic strategy for glioma. J Neurosci Res. 2024;102(1):e25254. PMID: 37814994
- Intranasal Delivery of Ivermectin Nanosystems as an Antitumor Agent: Focusing on Glioma Suppression. 2025. PMID: 40497800
- Repurposing Ivermectin and ATRA as Potential Therapeutics for Glioblastoma Multiforme. medRxiv preprint. 2024. DOI: 10.1101/2024.08.26.24312575
- Repurposing ivermectin: a new hope for glioblastoma multiforme? Med Chem Res. 2025. DOI: 10.1007/s00044-025-03435-z
Related: For general ivermectin dosing and protocol information, see our Ivermectin Protocol Guide.
🛒 Recommended Products
Affiliate links help support HighPeptides at no extra cost to you.
⚕️ Disclaimer
This page is for educational and informational purposes only. It is not medical advice. Always consult with a qualified healthcare provider before starting any supplement or medication. Data sourced from published peer-reviewed research. HighPeptides may receive affiliate compensation from linked vendors.